Patient Tissue-Derived FGFR4-Variant and Wild-Type Colorectal Cancer Organoid Development and Anticancer Drug Sensitivity Testing

Fibroblast growth factor receptor 4 (FGFR4)-variant and wild-type colorectal cancer (CRC) organoids were developed to investigate the effects of FGFR4-targeted drugs on CRC and their possible molecular mechanism.